Bradley Canino
Stock Analyst at Guggenheim
(4.44)
# 1,214
Out of 4,609 analysts
288
Total ratings
47.4%
Success rate
12.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Rated: Buy | $58 → $55 | $16.10 | +241.61% | 10 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $12.93 | +39.21% | 11 | Aug 3, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $125 → $135 | $106.41 | +26.87% | 21 | Jul 28, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $40 → $38 | $13.54 | +180.65% | 16 | Jul 23, 2026 | |
| ANTX AN2 Therapeutics | Initiated Coverage: Buy | $9 | $6.08 | +48.03% | 1 | Jul 19, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $31 | $19.76 | +56.88% | 18 | Jul 14, 2026 | |
| CELC Celcuity | Maintained: Buy | $165 | $93.25 | +76.94% | 15 | Jul 14, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $40 | $29.88 | +33.87% | 5 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $38 → $35 | $11.80 | +196.61% | 5 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Buy | $42 | $27.51 | +52.67% | 2 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $26 | $19.75 | +31.65% | 18 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $16.43 | +113.02% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $26.96 | +100.30% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $17.95 | +67.13% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $74.85 | +20.24% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $3.64 | +92.31% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.92 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $9.28 | - | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $3.75 | +33.33% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $5.00 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1.5 | $2.11 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 → $51 | $8.68 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $4.01 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $52.64 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $28.35 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 | $3.33 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $5.63 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $52.20 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $23.13 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $26.45 | n/a | 1 | Jul 8, 2020 |
Janux Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $58 → $55
Current: $16.10
Upside: +241.61%
ORIC Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $18
Current: $12.93
Upside: +39.21%
Kymera Therapeutics
Jul 28, 2026
Reiterated: Buy
Price Target: $125 → $135
Current: $106.41
Upside: +26.87%
Summit Therapeutics
Jul 23, 2026
Rated: Buy
Price Target: $40 → $38
Current: $13.54
Upside: +180.65%
AN2 Therapeutics
Jul 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $6.08
Upside: +48.03%
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $31
Current: $19.76
Upside: +56.88%
Celcuity
Jul 14, 2026
Maintained: Buy
Price Target: $165
Current: $93.25
Upside: +76.94%
Damora Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $40
Current: $29.88
Upside: +33.87%
Olema Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $38 → $35
Current: $11.80
Upside: +196.61%
Bicara Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $42
Current: $27.51
Upside: +52.67%
May 25, 2026
Maintained: Buy
Price Target: $22 → $26
Current: $19.75
Upside: +31.65%
Apr 29, 2026
Maintained: Buy
Price Target: $35
Current: $16.43
Upside: +113.02%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $26.96
Upside: +100.30%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $17.95
Upside: +67.13%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $74.85
Upside: +20.24%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $3.64
Upside: +92.31%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.92
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $9.28
Upside: -
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $3.75
Upside: +33.33%
Mar 27, 2025
Maintained: Buy
Price Target: $9
Current: $5.00
Upside: n/a
Mar 7, 2025
Maintained: Hold
Price Target: $3 → $1.5
Current: $2.11
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $63 → $51
Current: $8.68
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $4.01
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $52.64
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $28.35
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $68
Current: $3.33
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $5.63
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $52.20
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $23.13
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $26.45
Upside: n/a